Long-term Survival Outcomes Following Internal Mammary Node Irradiation in Stage II-III Breast Cancer: Results of a Large Retrospective Study With 13-year Follow-up

2012 ◽  
Vol 84 (3) ◽  
pp. S112
Author(s):  
J. Chang ◽  
W. Park ◽  
I. Lee ◽  
Y. Kim ◽  
C. Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Stage Ii ◽  
Survival Outcomes ◽  
Internal Mammary Node ◽  
Term Survival ◽  
Internal Mammary ◽  
Large Retrospective Study

Long-Term Survival Outcomes of Patients with Small (≤ 1 Centimetre) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study

Breast Care ◽  
2021 ◽  
Author(s):  
Jenni S. Liikanen ◽  
Marjut Leidenius ◽  
Heikki Joensuu ◽  
Tuomo J. Meretoja
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Disease Free Survival ◽  
Survival Outcomes ◽  
Her2 Expression ◽  
Term Survival ◽  
Node Negative ◽  
Her2 Breast Cancer

Introduction Human epidermal growth factor receptor 2 (HER2) expression is considered an unfavourable prognostic factor in early breast cancer when the patients are not treated with HER2-targeted therapy. However, the long-term prognostic importance of HER2-expression in small (≤1 cm, stage pT1a-b), node-negative HER2+ breast cancer is still incompletely known. Methods A retrospective analysis was performed based on a prospectively collected database including patients with pT1 breast cancer operated at the Helsinki University Hospital, Finland, between March 2000 and April 2006. In this database, 44 patients with pT1a-bN0M0, HER2+ cancer, not treated with adjuvant anti-HER2-targeted therapy (the HER2+ group) and 291 pT1a-bN0M0, hormone receptor positive, HER2- negative cancers (the ER+/HER2- group) were identified and included in the study. Survival outcomes were analysed using the Kaplan-Meier method. Results The median follow-up time was 9.7 years after primary breast surgery. Ten-year distant disease-free survival (DDFS) was 84.0% in the HER2+ group and 98.2% in the ER+/HER2- group (p < 0.001). Ten-year overall survival was only 78.5% in the HER2+ group, but 91.7% in the ER+/HER2- group (p = 0.09). Conclusions Cancer HER2-status is strongly associated with unfavourable DDFS during the first decade of follow-up in patients with small (pT1a-bN0M0) breast cancer when adjuvant anti-HER2-targeted treatment is not administered.

OC-0326: DBCG-IMN: Long-term survival gain with internal mammary node irradiation to breast cancer patients

2020 ◽  
Vol 152 ◽  
pp. S171-S172
Author(s):  
L.B.J. Thorsen ◽  
J. Overgaard ◽  
S.V. Holm-Hansen ◽  
M. Berg ◽  
I. Jensen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Internal Mammary Node ◽  
Term Survival ◽  
Long Term Survival ◽  
Survival Gain ◽  
Internal Mammary

scholarly journals Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up

2017 ◽  
Vol 44 ◽  
pp. 16-21 ◽  
Author(s):  
Michael H. Antoni ◽  
Jamie M. Jacobs ◽  
Laura C. Bouchard ◽  
Suzanne C. Lechner ◽  
Devika R. Jutagir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Depressive Symptoms ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Correction to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women

Breast Cancer ◽  
2018 ◽  
Vol 25 (2) ◽  
pp. 257-258
Author(s):  
Hitoshi Inari ◽  
Satoru Shimizu ◽  
Nobuyasu Suganuma ◽  
Tatsuya Yoshida ◽  
Hirotaka Nakayama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinicopathological Characteristics ◽  
Japanese Women ◽  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document